CN110151942A - 一种改善糖耐量和治疗糖尿病及肥胖症的药物及制备方法 - Google Patents
一种改善糖耐量和治疗糖尿病及肥胖症的药物及制备方法 Download PDFInfo
- Publication number
- CN110151942A CN110151942A CN201810218624.9A CN201810218624A CN110151942A CN 110151942 A CN110151942 A CN 110151942A CN 201810218624 A CN201810218624 A CN 201810218624A CN 110151942 A CN110151942 A CN 110151942A
- Authority
- CN
- China
- Prior art keywords
- parts
- obesity
- radix curcumae
- thallus laminariae
- sophora flower
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 208000008589 Obesity Diseases 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 title claims abstract description 26
- 235000020824 obesity Nutrition 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000219784 Sophora Species 0.000 claims abstract description 32
- 241001523383 Achnatherum Species 0.000 claims abstract description 22
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 21
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 21
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 21
- 241001105098 Angelica keiskei Species 0.000 claims abstract description 20
- 244000089759 Fortunella margarita Species 0.000 claims abstract description 20
- 235000019123 Fortunella margarita Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000605 extraction Methods 0.000 claims description 29
- 239000012141 concentrate Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 20
- 241000219095 Vitis Species 0.000 claims description 19
- 238000009835 boiling Methods 0.000 claims description 18
- 235000019441 ethanol Nutrition 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 12
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 240000006365 Vitis vinifera Species 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000008103 glucose Substances 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 229940100688 oral solution Drugs 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 244000175448 Citrus madurensis Species 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 241000585749 Achnatherum splendens Species 0.000 description 1
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000017317 Fortunella Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- -1 popular name for Chemical class 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种改善糖耐量和治疗糖尿病及肥胖症的药物及制备方法,包括以下重量份的原料:槐花10‑15份、郁金11‑18份、昆布2.4‑6份、葡萄籽6‑10份、芨芨草1.5‑3份、金橘根4‑8份和明日叶14‑21份。本发明原料来源广泛,制备工艺简单,在祖国传统中药对于糖尿病的病机研究基础之上,将槐花、郁金、昆布、葡萄籽、芨芨草、金橘根和明日叶进行科学合理的配伍,可起到相互协同的作用,共奏活血化瘀、滋阴清热、利水除湿的功效,从而能明显改善或缓解糖尿病的症状,且疗效显著、毒副作用小;本发明的产品还对肥胖症有良好的安全治疗效果。
Description
技术领域
本发明涉及一种药物,具体是一种改善糖耐量和治疗糖尿病及肥胖症的药物。
背景技术
随着我国社会经济的快速发展,人民物质生活水平不断提高,我国糖尿病病人的数量也在以惊人的速度急剧增多。糖尿病是一组由于胰岛素分泌缺陷和/或胰岛素作用障碍所致的以高血糖为特征的代谢性疾病。持续高血糖与长期代谢紊乱等可导致全身组织器官,特别是眼、肾、心血管及神经系统的损害及其功能障碍和衰竭。严重者可引起失水,电解质紊乱和酸碱平衡失调等急性并发症酮症酸中毒和高渗昏迷。
我国糖尿病增长幅度呈现出农村大于城市的显著特点。估计目前我国有糖尿病患者达3000多万人,主要是2型糖尿病。IGT者近6千万,其中有60%-70%的人是未获诊断的糖尿病人,两者总计人数已达近1亿。我国已成为仅次于印度的世界第二大糖尿病大国。在60岁以上的人群中2型糖尿病患病率高达11.34%,IGT达11.62%。在65岁至74岁的人群中,糖尿病人和IGT者加起来可占该年龄段总人数的40%,预测到2025年中国糖尿病人数将达5000万。糖尿病的广泛流行,越来越成为一个严重的社会卫生问题。
口服药物和多次皮下注射胰岛素是常见的糖尿病治疗方式。口服药物主要用于治疗DM2,对于DM2患者而言,其本身胰腺功能已经受损,药物再进入胰腺细胞刺激B细胞分泌胰岛素,这样超负荷工作,只会加速胰腺B细胞的衰竭,最终导致药物治疗失效;口服药物只能控制DM2的餐后血糖,对其他时段的血糖控制完全起不到作用,不能将全天24小时血糖控制平稳,所以并不能阻止或延缓并发症的发生。多次皮下注射胰岛素每天需要定时注射2-5次,不能完全满足DM患者自身的生理需要,无法应付不可预测的胰岛素需求量,对计划外事件亦不能应付自如,不能阻断或减少胰岛素的持续吸收,一旦发生低血糖,就必须额外进食,对血糖控制不利;降糖速度较慢,胰岛素用量大,极易发生意外低血糖。
中医药在糖尿病的预防和治疗等方面历史久远,中医认为,“二阳结谓之消”,认为胃肠燥热,导致津液亏损是糖尿病的发病的主要病机。针对阴虚燥热基本病机,中医历代医家对其进行不断的探索,总结其治法应当以滋阴清热主。此外,还有许多研究应用活血化瘀、补肾、补虚泻实等治疗糖尿病,均取得了良好效果。中医治疗糖尿病不但不良反应小,而且还能增强机体免疫力,改善糖尿病症状,中药治疗对糖尿病治疗有积极的意义。
发明内容
本发明的目的在于提供一种改善糖耐量和治疗糖尿病及肥胖症的药物,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种改善糖耐量和治疗糖尿病及肥胖症的药物,包括以下重量份的原料:槐花10-15份、郁金11-18份、昆布2.4-6份、葡萄籽6-10份、芨芨草1.5-3份、金橘根4-8份和明日叶14-21份。
作为本发明进一步的方案:所述改善糖耐量和治疗糖尿病及肥胖症的药物,包括以下重量份的原料:槐花12-15份、郁金14-18份、昆布3.5-6份、葡萄籽7.5-10份、芨芨草2.1-3份、金橘根5.5-8份和明日叶17-21份。
作为本发明进一步的方案:所述改善糖耐量和治疗糖尿病及肥胖症的药物,包括以下重量份的原料:槐花13.6份、郁金16份、昆布5份、葡萄籽9份、芨芨草2.6份、金橘根7.2份和明日叶19.5份。
槐花味苦、性微寒,归肝、大肠经;入血敛降,体轻微散;具有凉血止血,清肝泻火的功效;主治肠风便血,痔血,血痢,尿血,血淋,崩漏,吐血,衄血,肝火头痛,目赤肿痛,喉痹,失音,痈疽疮疡,对吐血、尿血、痔疮出血、风热目赤、高血压病、高脂血症、颈淋巴结核、血管硬化、大便带血、糖尿病、视网膜炎、银屑病等有显著疗效。
郁金性味辛、苦,寒,归肝、心、肺经,具有活血止痛,行气解郁,清心凉血,利胆退黄的作用,主治胸胁刺痛,胸痹心痛,经闭痛经,乳房胀痛,热病神昏,癫痫发狂,血热吐衄,黄疸尿赤。
昆布气腥,味咸,归肝、胃、肾经。有软坚散结,消痰,利水之功能,用于痰饮水肿,软坚散结,消痰,利水,瘿瘤、瘰疬、睾丸肿痛和痰饮水肿。
葡萄籽富含100多种有效物质,其中不饱和脂肪酸-----亚油酸(是一种人体必需但不能合成的)占68-76%居油料作物之首,它由不饱和到饱和状态要消耗20%的胆固醇,能够有效的降低血脂;葡萄籽能有效清除体内多余的自由基,保护人体器官和组织,防治心脏病、癌症、早衰、糖尿病、动脉硬化等100多种由自由基所引起的疾病。
芨芨草是禾本科芨芨草,Achnatherum splendens(Trin.)Nevski,以茎基部及花、根状茎入药。性味甘、淡,平,具有利尿清热的作用。
金橘根是芸香科金橘Fortunella margarita(Lour.)Swingle,以根、果实入药。性味辛、苦,温,具有醒脾行气的作用。主治风寒咳嗽、胃气痛、食积胀满和疝气。
明日叶有清热,利尿,强壮,催乳之效,可以用于治高血压,低血压,动脉硬化症,狭心症,心悸,糖尿病,肝病,肝硬化,感冒,气喘,蓄脓症,胃肠病,风湿病,坐骨神经痛,失眠症,乳汁不足,肺癌,胃癌。
所述改善糖耐量和治疗糖尿病及肥胖症的药物的制备方法,具体步骤如下:
步骤一,将葡萄籽、芨芨草和金橘根混合,得到第一混合物,在第一混合物中加入其总重量4-6倍的水煮沸提取3-4次,煮沸时间为每次80-120分钟,合并每次的提取液并且过滤,减压浓缩,得到浓缩液,向浓缩液中加入质量分数为80-85%的乙醇至醇的质量分数为60-70%,滤出沉淀,回收乙醇,浓缩后得到第一浓缩液;
步骤二,将槐花、郁金、昆布和明日叶分别粉碎后装入超临界CO2萃取釜中进行超临界CO2萃取,萃取的压力控制在8-12MPa,萃取温度40-60摄氏度,得到槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物;
步骤三,将第一浓缩液、槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物混合、浓缩成相对密度为1.02-1.15的清膏;
步骤四,将清膏趁热过200-400目筛滤过,滤液进行喷雾干燥,即得喷干粉。
作为本发明进一步的方案:喷雾干燥条件为:出口温度75-96摄氏度,进口温度130-160摄氏度,流速8-12%,料液温度23-30摄氏度。
作为本发明进一步的方案:将喷干粉加入药学上可接受的辅料,制成丸剂、片剂、胶囊剂、散剂、颗粒剂、口服液。
与现有技术相比,本发明的有益效果是:本发明原料来源广泛,制备工艺简单,在祖国传统中药对于糖尿病的病机研究基础之上,将槐花、郁金、昆布、葡萄籽、芨芨草、金橘根和明日叶进行科学合理的配伍,可起到相互协同的作用,共奏活血化瘀、滋阴清热、利水除湿的功效,从而能明显改善或缓解糖尿病的症状,且疗效显著、毒副作用小;本发明的产品还对肥胖症有良好的安全治疗效果。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种改善糖耐量和治疗糖尿病及肥胖症的药物,包括以下重量份的原料:槐花10份、郁金11份、昆布2.4份、葡萄籽6份、芨芨草1.5份、金橘根4份和明日叶14份。
所述改善糖耐量和治疗糖尿病及肥胖症的药物的制备方法,具体步骤如下:
步骤一,将葡萄籽、芨芨草和金橘根混合,得到第一混合物,在第一混合物中加入其总重量5倍的水煮沸提取3次,煮沸时间为每次90分钟,合并每次的提取液并且过滤,减压浓缩,得到浓缩液,向浓缩液中加入质量分数为80%的乙醇至醇的质量分数为66%,滤出沉淀,回收乙醇,浓缩后得到第一浓缩液;
步骤二,将槐花、郁金、昆布和明日叶分别粉碎后装入超临界CO2萃取釜中进行超临界CO2萃取,萃取的压力控制在9.6MPa,萃取温度48摄氏度,得到槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物;
步骤三,将第一浓缩液、槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物混合、浓缩成相对密度为1.06的清膏;
步骤四,将清膏趁热过240目筛滤过,滤液进行喷雾干燥,喷雾干燥条件为:出口温度88摄氏度,进口温度145摄氏度,流速10%,料液温度26摄氏度,即得喷干粉。
实施例2
一种改善糖耐量和治疗糖尿病及肥胖症的药物,包括以下重量份的原料:槐花12份、郁金14份、昆布3.5份、葡萄籽7.5份、芨芨草2.1份、金橘根5.5份和明日叶17份。
所述改善糖耐量和治疗糖尿病及肥胖症的药物的制备方法,具体步骤如下:
步骤一,将葡萄籽、芨芨草和金橘根混合,得到第一混合物,在第一混合物中加入其总重量6倍的水煮沸提取3次,煮沸时间为每次110分钟,合并每次的提取液并且过滤,减压浓缩,得到浓缩液,向浓缩液中加入质量分数为80%的乙醇至醇的质量分数为65%,滤出沉淀,回收乙醇,浓缩后得到第一浓缩液;
步骤二,将槐花、郁金、昆布和明日叶分别粉碎后装入超临界CO2萃取釜中进行超临界CO2萃取,萃取的压力控制在10MPa,萃取温度54摄氏度,得到槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物;
步骤三,将第一浓缩液、槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物混合、浓缩成相对密度为1.12的清膏;
步骤四,将清膏趁热过320目筛滤过,滤液进行喷雾干燥,即得喷干粉,将喷干粉加入药学上可接受的辅料,制成丸剂、片剂、胶囊剂、散剂、颗粒剂、口服液。
实施例3
一种改善糖耐量和治疗糖尿病及肥胖症的药物,包括以下重量份的原料:槐花13.6份、郁金16份、昆布5份、葡萄籽9份、芨芨草2.6份、金橘根7.2份和明日叶19.5份。
所述改善糖耐量和治疗糖尿病及肥胖症的药物的制备方法,具体步骤如下:
步骤一,将葡萄籽、芨芨草和金橘根混合,得到第一混合物,在第一混合物中加入其总重量4倍的水煮沸提取4次,煮沸时间为每次108分钟,合并每次的提取液并且过滤,减压浓缩,得到浓缩液,向浓缩液中加入质量分数为84%的乙醇至醇的质量分数为68%,滤出沉淀,回收乙醇,浓缩后得到第一浓缩液;
步骤二,将槐花、郁金、昆布和明日叶分别粉碎后装入超临界CO2萃取釜中进行超临界CO2萃取,萃取的压力控制在10.5MPa,萃取温度55摄氏度,得到槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物;
步骤三,将第一浓缩液、槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物混合、浓缩成相对密度为1.15的清膏;
步骤四,将清膏趁热过360目筛滤过,滤液进行喷雾干燥,喷雾干燥条件为:出口温度92摄氏度,进口温度150摄氏度,流速10%,料液温度28摄氏度,即得喷干粉。
实施例4
一种改善糖耐量和治疗糖尿病及肥胖症的药物,包括以下重量份的原料:槐花15份、郁金18份、昆布6份、葡萄籽10份、芨芨草3份、金橘根8份和明日叶21份。
所述改善糖耐量和治疗糖尿病及肥胖症的药物的制备方法,具体步骤如下:
步骤一,将葡萄籽、芨芨草和金橘根混合,得到第一混合物,在第一混合物中加入其总重量5倍的水煮沸提取3次,煮沸时间为每次86分钟,合并每次的提取液并且过滤,减压浓缩,得到浓缩液,向浓缩液中加入质量分数为82%的乙醇至醇的质量分数为65%,滤出沉淀,回收乙醇,浓缩后得到第一浓缩液;
步骤二,将槐花、郁金、昆布和明日叶分别粉碎后装入超临界CO2萃取釜中进行超临界CO2萃取,萃取的压力控制在8-12MPa,萃取温度40-60摄氏度,得到槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物;
步骤三,将第一浓缩液、槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物混合、浓缩成相对密度为1.07的清膏;
步骤四,将清膏趁热过300目筛滤过,滤液进行喷雾干燥,喷雾干燥条件为:出口温度84摄氏度,进口温度155摄氏度,流速12%,料液温度26摄氏度,即得喷干粉,将喷干粉加入药学上可接受的辅料,制成丸剂、片剂、胶囊剂、散剂、颗粒剂、口服液。
对比例1
除不含有芨芨草,其余组分和制备方法均与实施例2相同。
对比例2
采用实施例3的组分,但是将组分直接研磨成粉末,然后加入药学上可接受的辅料,制成丸剂、片剂、胶囊剂、散剂、颗粒剂、口服液。
进行动物实验,选择健康小白鼠共100只,雌雄各半,体重范围是25-30g。随机分成三组,其中正常组20只,模型组20只,治疗组60只,再将治疗组随机平均分为治疗1组、治疗2组、治疗3组、治疗4组、治疗5组和治疗6组。对模型组和治疗组用四氧嘧啶腹腔注射,剂量为220mg/kg体重,48小时后,测定空腹6小时血糖,空腹血糖≥8.0mmol/L为建模成功。治疗1组、治疗2组、治疗3组、治疗4组、治疗5组和治疗6组分别用实施例1、实施例2、实施例3、实施例4、对比例1和对比例2的成品治疗,每只灌胃0.4g,每天一次,连续7天,模型组用等量蒸馏水灌胃,测定造模前后,实验结束的空腹血糖。实验结束取眼球血离心,分离血清,测定总胆固醇、甘油三脂、尿素和总蛋白的浓度,血糖结果见表1。
表1
造模前/mmol/L | 造模后/mmol/L | 治疗后/mmol/L | |
正常组 | 3.38±0.56 | 3.62±0.84 | 4.17±0.46 |
模型组 | 3.18±0.87 | 12.04±1.68 | 11.89±1.92 |
治疗1组 | 3.32±0.68 | 12.38±2.47 | 4.26±1.12 |
治疗2组 | 3.46±0.75 | 11.96±2.24 | 4.11±1.87 |
治疗3组 | 3.87±0.84 | 12.52±3.86 | 4.06±2.17 |
治疗4组 | 3.66±0.92 | 11.87±2.62 | 3.98±2.69 |
治疗5组 | 3.64±1.04 | 12.38±4.52 | 10.87±1.64 |
治疗6组 | 3.57±0.98 | 12.24±2.34 | 11.26±3.18 |
表1可以看出,造模后模型组和治疗组小鼠的血糖明显升高,在用本申请实施例1-4的中药组合物治疗后,治疗1-4组的小鼠血糖明显下降,采用对比例1-2组的中药组合物治疗后,治疗5-6组的小鼠血糖略微下降。
对各组小鼠试验前后血清成分含量变化结果(P<0.01),测试结果见表2。
表2
表2中可以看出试验前模型组和治疗组的总蛋白含量均低于正常组,但是经过治疗后,治疗1-4组的总蛋白含量明显高于模型组,治疗5-6组的总蛋白含量略微高于模型组,说明药物促进了机体内蛋白的合成。通常糖尿病会伴有胆固醇和甘油三酯等浓度升高,但是与模型组相比,治疗1-4组在试验后胆固醇和甘油三酯的含量明显减少,治疗5-6组在试验后胆固醇和甘油三酯的含量略微减少,说明本发明的中药组合物还具有一定的降脂作用。另外,与模型组相比,试验后的治疗1-4组尿素含量明显降低,试验后的治疗5-6组尿素含量明显降低表明本发明的中药组合物对肾脏有一定的保护作用。
本发明的中药组合物不仅能降低血糖含量,还能缓解因糖代谢异常导致的机体迅速消瘦,另外,本发明的中药组合物还可以减少血清总的胆固醇和甘油三酯含量,并且有利地增加总蛋白的含量,由此证明本发明的中药组合物能明显缓解糖尿病的症状,对于糖尿病患者具有显著的治疗效果。
姚某,男,36岁。经医院诊断为II型糖尿病,尿糖(++),空腹血糖12.9mmol/L,腰膝酸软,精神疲乏,大便干燥。服用本发明实施例1的产品,每日两次,两个月为一个疗程。一个疗程后复查,空腹血糖5.6mmoI/L,尿糖(一),又连续治疗两疗程,停药,随访至今未复发。
王某,女,60岁。主诉患有糖尿病1年,检测空腹血糖8.6mmoL/L,甘油三脂1.83mmoL/L,高密度脂蛋白0.98mmoL/L,低密度脂蛋白5.02mmoL/L,总胆固醇6.95mmoL/L,诊断为糖尿病合并高脂血症。服用本发明实施例3的产品,每日两次,两个月为一个疗程。一个疗程后复查,各项指标正常,一年后随访血脂未见异常。
商某,男,36岁。主诉最近几个月浑身乏力,体型消瘦,饭量虽然增加,但是体重未见增长,腰酸腿痛,大便干燥,经医院诊断为II型糖尿病。服用本发明实施例4的产品,每日两次,两个月为一个疗程。一个疗程后复查,空腹血糖5.6mmoI/L,体重增加,并且诸症消除。
选择200例肥胖症的门诊患者,其中男100例,女100例,年龄20-46岁。随机分为治疗组120例,对照组80例。两组性别、年龄、病情等资料均无显著性差异,具有可比性,治疗组随机平均分为治疗1组、治疗2组、治疗3组、治疗4组、治疗5组和治疗6组,对照组服用市面上的减肥茶,按照说明书服用,治疗1组、治疗2组、治疗3组、治疗4组、治疗5组和治疗6组分别用实施例1、实施例2、实施例3、实施例4、对比例1和对比例2的成品治疗,每天2次,坚持一个半月。
治疗标准:显效:体重下降15%以上,停药三个月未见反弹。有效:体重增加得到控制,或者下降0-15%。无效:无明显疗效或体重继续增加。治疗结果见表3。
表3
显效 | 好转 | 无效 | 有效率/% | |
对照组 | 0 | 12 | 8 | 60 |
治疗1组 | 8 | 11 | 1 | 95 |
治疗2组 | 6 | 13 | 1 | 95 |
治疗3组 | 10 | 10 | 0 | 100 |
治疗4组 | 7 | 11 | 2 | 90 |
治疗5组 | 1 | 15 | 4 | 80 |
治疗6组 | 2 | 13 | 5 | 75 |
从表3中可以看出治疗1-4组患者的有效率明显高于对照组,治疗5-6组患者的有效率略微高于对照组。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (6)
1.一种改善糖耐量和治疗糖尿病及肥胖症的药物,其特征在于,包括以下重量份的原料:槐花10-15份、郁金11-18份、昆布2.4-6份、葡萄籽6-10份、芨芨草1.5-3份、金橘根4-8份和明日叶14-21份。
2.根据权利要求1所述的改善糖耐量和治疗糖尿病及肥胖症的药物,其特征在于,包括以下重量份的原料:槐花12-15份、郁金14-18份、昆布3.5-6份、葡萄籽7.5-10份、芨芨草2.1-3份、金橘根5.5-8份和明日叶17-21份。
3.根据权利要求1所述的改善糖耐量和治疗糖尿病及肥胖症的药物,其特征在于,包括以下重量份的原料:槐花13.6份、郁金16份、昆布5份、葡萄籽9份、芨芨草2.6份、金橘根7.2份和明日叶19.5份。
4.一种如权利要求1-3任一所述的改善糖耐量和治疗糖尿病及肥胖症的药物的制备方法,其特征在于,具体步骤如下:
步骤一,将葡萄籽、芨芨草和金橘根混合,得到第一混合物,在第一混合物中加入其总重量4-6倍的水煮沸提取3-4次,煮沸时间为每次80-120分钟,合并每次的提取液并且过滤,减压浓缩,得到浓缩液,向浓缩液中加入质量分数为80-85%的乙醇至醇的质量分数为60-70%,滤出沉淀,回收乙醇,浓缩后得到第一浓缩液;
步骤二,将槐花、郁金、昆布和明日叶分别粉碎后装入超临界CO2萃取釜中进行超临界CO2萃取,萃取的压力控制在8-12MPa,萃取温度40-60摄氏度,得到槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物;
步骤三,将第一浓缩液、槐花萃取物、郁金萃取物、昆布萃取物和明日叶萃取物混合、浓缩成相对密度为1.02-1.15的清膏;
步骤四,将清膏趁热过200-400目筛滤过,滤液进行喷雾干燥,即得喷干粉。
5.根据权利要求4所述的改善糖耐量和治疗糖尿病及肥胖症的药物的制备方法,其特征在于,所述喷雾干燥条件为:出口温度75-96摄氏度,进口温度130-160摄氏度,流速8-12%,料液温度23-30摄氏度。
6.根据权利要求4所述的改善糖耐量和治疗糖尿病及肥胖症的药物的制备方法,其特征在于,所述喷干粉加入药学上可接受的辅料,制成丸剂、片剂、胶囊剂、散剂、颗粒剂、口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810218624.9A CN110151942A (zh) | 2018-03-16 | 2018-03-16 | 一种改善糖耐量和治疗糖尿病及肥胖症的药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810218624.9A CN110151942A (zh) | 2018-03-16 | 2018-03-16 | 一种改善糖耐量和治疗糖尿病及肥胖症的药物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110151942A true CN110151942A (zh) | 2019-08-23 |
Family
ID=67636190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810218624.9A Withdrawn CN110151942A (zh) | 2018-03-16 | 2018-03-16 | 一种改善糖耐量和治疗糖尿病及肥胖症的药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110151942A (zh) |
-
2018
- 2018-03-16 CN CN201810218624.9A patent/CN110151942A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102258708B (zh) | 一种养生酒及其制备方法 | |
CN108391774A (zh) | 一种抗痛风的功能饮料及其制备方法 | |
CN104208302A (zh) | 一种降血脂的金樱子保健口服液及其制备方法 | |
CN108277138A (zh) | 一种保健养生酒及其制备方法 | |
CN105505727A (zh) | 一种明目提神的醋饮 | |
CN106075020A (zh) | 一种具有治疗糖尿病功效的灵芝复方颗粒剂 | |
CN104450470A (zh) | 一种柘果保健酒及其制备方法 | |
CN104324261A (zh) | 治疗高血糖的药物组合物及其制备方法 | |
CN107441401A (zh) | 用于降三高的中药组合物及其制备方法 | |
CN104082670B (zh) | 一种具有降血压功效的养生粥及其制作方法 | |
CN110151942A (zh) | 一种改善糖耐量和治疗糖尿病及肥胖症的药物及制备方法 | |
CN103082298B (zh) | 一种用于辅助降糖的保健食品及其制备方法 | |
CN105770798A (zh) | 一种用于治疗风痰瘀血及痹阻经络型脑梗死的中药 | |
CN110882362A (zh) | 一种调理糖尿病的中药食疗制品及其制备方法 | |
CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
CN110064021A (zh) | 一种治疗高血压的中药组合物及其制备方法 | |
CN109260412A (zh) | 一种治疗近视的中药组合物 | |
CN103845671B (zh) | 心力衰竭温阳益气散及制备方法 | |
CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN109090402A (zh) | 一种含有荔枝皮提取物的保健饮料及其加工方法 | |
CN108004090A (zh) | 一种保健药酒及其制备方法 | |
CN106728828A (zh) | 一种治疗冠心病的中药制剂及其制备工艺 | |
CN103907931A (zh) | 一种降压保健品及其制备方法 | |
CN104840727B (zh) | 具有抗食道癌活性的中药组合物及其制备方法和应用 | |
CN104306553B (zh) | 一种降血脂的食品、保健品或药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201201 Address after: Room E201, 3100 Hutai Road, Baoshan District, Shanghai, 200444 Applicant after: Shanghai Likang precision medical technology Co., Ltd Address before: 200000 3008, room 3, 6 building, 1868 lane, Huang Xing Road, Yangpu District, Shanghai. Applicant before: SHANGHAI CHINA BETTER-LIFE MEDICAL TECHNOLOGY Co.,Ltd. |
|
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190823 |